Home  >>  About ROXRO  >>  Letter from the CEO

Letter from the CEO

To Our Friends and Supporters,

Welcome to ROXRO Pharma's new website. We hope you find it site to be both informative and easy to navigate.

We've launched the new site following a series of significant accomplishments for our young company. I am pleased to announce that the FDA has accepted our New Drug Application for ROX-888, our intranasal pain reliever for review.

Meanwhile, we are currently evaluating the possibility of working with a partner to support the sales and marketing activities required to launch ROX-888. Our research continues to confirm strong market interest in this novel, patient-friendly product.

I am also pleased to note that we have completed Phase 2 studies of our second novel product, ROX-828, which is an intranasal treatment for migraine. We expect the data from these studies to be available in the third quarter of this year, which will inform our decision-making as we move ahead.

I look forward to keeping you apprised of our activities and accomplishments through this website. All of us at ROXRO Pharma appreciate your interest and continued support.

Roberto Rosenkranz, Ph.D.,
Chief Executive Officer and Chairman